文献速递消化道肿瘤与早癌消化内镜

CTNNA1截短变异与遗传性弥漫性胃癌:351个家系及37000余对照解读

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls.
PubMed 文献 · Gut · 2026-04-07

据此提出简化版「Porto」基因检测标准,携带家系检出率提高9%且性能不劣于HDGC 2020指南。

要点

  • CTNNA1截短变异经NMD降解致αE-catenin缺失,携带者弥漫性胃癌风险为非截短携带者的8倍。
  • CTNNA1截短携带者胃癌和乳腺小叶癌风险分别比CDH1致病/可能致病变异携带者低5倍和8倍。
  • 「Porto」标准简化CTNNA1基因检测,携带家系检出率提高9%且性能不劣于HDGC 2020指南。

核心结论

  • CTNNA1截短变异与弥漫性胃癌和乳腺小叶癌正相关,NMD是其功能丧失的病理生理机制。
  • 与CDH1相比,CTNNA1是中等外显率的遗传性弥漫性胃癌基因。
  • 上述证据可用于制定CTNNA1携带者个体的监测和/或预防措施。

研究设计与样本

  • 采用CRISPR/Cas9 CTNNA1敲除胃癌细胞和CTNNA1人源化果蝇评估功能丧失机制。

主要发现

  • CTNNA1截短转录本经NMD降解,携带者弥漫性胃癌丢失αE-catenin,且截短转录本在果蝇中无功能。
  • 截短携带者弥漫性胃癌风险为非截短携带者的8倍。
  • CTNNA1截短携带者胃癌和乳腺小叶癌风险分别比CDH1致病/可能致病变异携带者低5倍和8倍。
  • 与野生型相比,CTNNA1截短和CDH1截短携带者胃癌风险分别高7倍和38倍。
  • 乳腺小叶癌在CTNNA1截短携带者中反复出现,部分不符合HDGC标准;斑状营养不良2型与非截短变异(αE-catenin M片段)正相关。

关键数值与推荐

  • 既往研究估计CTNNA1变异携带者80岁时弥漫性胃癌终生风险为49-57%。
  • 与野生型相比,CTNNA1截短携带者胃癌风险高7倍,CDH1截短携带者高38倍。
  • CTNNA1截短携带者胃癌和乳腺小叶癌风险分别比CDH1致病/可能致病变异携带者低5倍和8倍。
  • 简化既往CTNNA1基因检测标准形成的「Porto」标准使携带家系检出率提高9%,性能不劣于HDGC 2020临床指南。

临床怎么用

  • CTNNA1截短变异携带者应纳入弥漫性胃癌和乳腺小叶癌监测及风险降低讨论。
  • 可采用「Porto」标准简化CTNNA1基因检测,提高携带家系检出率。
  • CTNNA1为中等外显率基因,监测和预防措施需区别于CDH1高外显率携带者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse gastric cancer (DGC) is the most common manifestation in germline CTNNA1 variant carriers, with one study estimating a 49-57% lifetime risk by age 80. Knowledge on CTNNA1-associated hereditary diffuse gastric cancer (HDGC), loss-of-function mechanisms, variant-type causality, disease spectrum and cancer risks remains scarce. OBJECTIVE: Explore CTNNA1 genotype-phenotype associations to improve genetic testing criteria, surveillance and risk-reduction recommendations for carriers. DESIGN: Using molecular, clinical and population data from 1308 individuals from 351 CTNNA1-variant carrier families and 37 428 non-carriers from European and American ancestries, we analysed genotype-phenotype associations with multivariable logistic regression. With CRISPR/Cas9 CTNNA1-knockout gastric cancer (GC) cells and CTNNA1-humanised Drosophila, we assessed CTNNA1-associated loss-of-function mechanisms. RESULTS: CTNNA1-truncating transcripts are degraded by nonsense-mediated mRNA decay (NMD), and DGCs from germline CTNNA1-truncating carriers lose αE-catenin. These transcripts are non-functional in Drosophila, in contrast to non-truncating transcripts. DGC risk is eightfold higher in truncating, compared with non-truncating carriers. The risk of GC and lobular breast cancer (LBC) development in CTNNA1-truncating variant carriers is fivefold and eightfold lower than in CDH1 pathogenic/likely pathogenic variant carriers, respectively. Compared with wild-type individuals, GC risk is 7-fold higher in CTNNA1-truncating and 38-fold higher in CDH1-truncating variant carriers. LBC is recurrent among CTNNA1-truncating carriers, some lacking HDGC criteria. Simplification of previous criteria for CTNNA1 genetic testing produced the 'Porto' criteria, which increased CTNNA1-carrier families' pick-up rate by 9%, without performance loss compared with the HDGC 2020 clinical guidelines. Macular dystrophy patterned-2 was positively associated with non-truncating variants, specifically in the αE-catenin M-fragment. CONCLUSION: We provide compelling evidence supporting that CTNNA1-truncating variants positively associate with DGC and LBC, and NMD as the pathophysiological mechanism leading to CTNNA1 downregulation. We demonstrate that compared with CDH1, CTNNA1 is a moderate penetrance HDGC gene. This new knowledge is essential to define surveillance and/or prophylactic measures for CTNNA1-carrier individuals and families.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lobo S, Dias A, Pedro AM, et al. Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls. Gut. 2026. PMID: 40998418. doi:10.1136/gutjnl-2024-334601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。